Insider Selling: David Persing Sells 5,000 Shares of Cepheid Stock (CPHD)
Cepheid (NASDAQ:CPHD) VP David Persing unloaded 5,000 shares of the company’s stock on the open market in a transaction dated Monday, September 16th. The stock was sold at an average price of $38.95, for a total value of $194,750.00. Following the completion of the sale, the vice president now directly owns 177 shares in the company. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on CPHD shares. Analysts at UBS AG reiterated a “buy” rating on shares of Cepheid (NASDAQ:CPHD) in a research note to investors on Thursday, September 5th. They now have a $40.00 price target on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Cepheid (NASDAQ:CPHD) from $39.00 to $42.00 in a research note to investors on Thursday, September 5th. They now have an “outperform” rating on the stock. Finally, analysts at Wedbush reiterated a “buy” rating on shares of Cepheid (NASDAQ:CPHD) in a research note to investors on Monday, August 19th. They now have a $37.00 price target on the stock.
Three analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $40.56.
Cepheid (NASDAQ:CPHD) traded up 0.41% during mid-day trading on Wednesday, hitting $39.10. The stock had a trading volume of 461,740 shares. Cepheid has a one year low of $28.12 and a one year high of $40.70. The stock’s 50-day moving average is $36.38 and its 200-day moving average is $36.48. The company’s market cap is $2.637 billion.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Thursday, July 18th. The company reported $0.02 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.04 by $0.02. The company had revenue of $96.00 million for the quarter, compared to the consensus estimate of $92.57 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue for the quarter was up 18.5% on a year-over-year basis. Analysts expect that Cepheid will post $-0.26 EPS for the current fiscal year.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.